+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating XEN1101 as an additional treatment for people with primary generalized tonic-clonic seizures PGTCS in this Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. The study aims to assess the clinical efficacy, safety, and tolerability of XEN1101 in subjects diagnosed with generalized epilepsy who are currently taking 1 to 3 anti-seizure medications ASMs. Participants must have probable or possible PGTCS and meet specific inclusion criteria. Participants aged 12 years and older will be randomly assigned to receive either XEN1101 or a placebo. Those 18 years and older will receive 25 mg of XEN1101 or placebo daily, while those between 12 and under 18 years may receive 15 mg, 25 mg, or placebo once daily with an evening meal. The study includes a baseline period lasting up to 9.5 weeks to monitor seizure frequency, followed by a 12-week double-blind treatment period. After completing this phase, participants can enter an open-label extension study to continue XEN1101 treatment or join an 8-week post-treatment follow-up. Throughout the study, participants will keep accurate seizure diaries and undergo assessments to measure the median percent change in monthly PGTCS frequency. The study will also monitor safety and tolerability during treatment. Those who do not continue into the extension phase will have follow-up visits for 8 weeks after treatment ends. Overall, the trial involves multiple visits and careful monitoring to evaluate the impact of XEN1101 as adjunctive therapy over several months.

Age: 12Years +All GendersPhase 3
141 locations
S

Actively Recruiting

Researchers are studying the use of carisbamate YKP509 as an additional treatment to reduce drop seizures in children and adults aged 4 to 55 years with Lennox Gastaut Syndrome LGS. This trial aims to compare carisbamate to a placebo in lowering the number of tonic, atonic, and tonic-clonic seizures. Secondary goals include assessing the overall seizure reduction, safety, tolerability, and how the drug behaves in the body. Participants receive carisbamate or placebo twice daily with doses adjusted based on age and weight. Children aged 4 to under 12 years receive weight-based dosing, while those 12 years and older follow fixed dosing schedules. The study includes a titration period to reach maintenance doses. Some participants may join an optional open-label extension. The study is randomized and double-blind, meaning neither participants nor researchers know who receives carisbamate or placebo. During the trial, participants and caregivers will track seizures using diaries. Regular assessments will measure seizure frequency changes over time, including the primary outcome of percentage change in drop seizures during the double-blind period lasting up to three years. Researchers will also evaluate global impressions of change and monitor safety through clinical evaluations. The total study duration includes baseline, treatment, and follow-up periods, ensuring thorough monitoring of effects and safety.

Age: 4Years - 55YearsAll GendersPhase 3
71 locations